TAUNS LABORATORIES,INC. Financials TAUNS Laboratories,Inc.
Equities
197A
JP3452250008
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 410 JPY | 0.00% |
|
-1.44% | 0.00% |
Valuation
| Fiscal Period: June | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 41,000 | 41,000 | - | - |
| Enterprise Value (EV) 1 | 41,000 | 40,846 | 44,756 | 47,837 |
| P/E ratio | - | 7.42 x | 6.84 x | 5.89 x |
| Yield | - | 4.12% | 6.47% | 5.24% |
| Capitalization / Revenue | 2.62 x | 2.32 x | 2.16 x | 2.08 x |
| EV / Revenue | 2.62 x | 2.31 x | 2.36 x | 2.43 x |
| EV / EBITDA | - | 4.77 x | 4.61 x | 5.4 x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | 3.65 x | 2.6 x | 2.09 x |
| Nbr of stocks (in thousands) | 100,000 | 100,000 | - | - |
| Reference price 2 | 410.0 | 410.0 | 410.0 | 410.0 |
| Announcement Date | 17/05/24 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | 15,673 | 17,676 | 18,988 | 19,670 |
| EBITDA 1 | - | 8,567 | 9,701 | 8,855 |
| EBIT 1 | - | 7,796 | 8,412 | 7,835 |
| Operating Margin | - | 44.1% | 44.3% | 39.83% |
| Earnings before Tax (EBT) 1 | - | 7,700 | 7,800 | 12,000 |
| Net income 1 | 3,035 | 5,525 | 5,993 | 6,957 |
| Net margin | 19.36% | 31.26% | 31.56% | 35.37% |
| EPS 2 | - | 55.25 | 59.92 | 69.56 |
| Free Cash Flow | - | - | - | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share 2 | - | 16.88 | 26.52 | 21.50 |
| Announcement Date | 17/05/24 | - | - | - |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt 1 | - | - | 3,756 | 6,837 |
| Net Cash position 1 | - | 154 | - | - |
| Leverage (Debt/EBITDA) | - | - | 0.3871 x | 0.772 x |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 65.4% | 57.7% | 34.9% |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share 2 | - | 112.0 | 158.0 | 196.0 |
| Cash Flow per Share | - | - | - | - |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 17/05/24 | - | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
410
JPY
Average target price
460
JPY
Spread / Average Target
+12.20%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 254M | |
| -6.61% | 11.96B | |
| -19.37% | 6.6B | |
| +6.63% | 5.75B | |
| +26.87% | 5.51B | |
| -21.19% | 3.48B | |
| +6.64% | 2.51B | |
| +30.33% | 2.26B | |
| -66.60% | 2.24B | |
| -12.28% | 2.19B |
- Stock Market
- Equities
- 197A Stock
- Financials TAUNS Laboratories,Inc.
